Diabetic Ketoacidosis News and Research

RSS

Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.

24 Sep 2018

Insulin’s high cost leads to deadly rationing

Diabetic ketoacidosis is a terrible way to die. It’s what happens when you don’t have enough insulin. Your blood sugar gets so high that your blood becomes highly acidic, your cells dehydrate, and your body stops functioning.

7 Sep 2018

Scientists demonstrate how medical test results can be remotely modified

A team of physicians and computer scientists at the University of California has shown that it is easy to modify medical test results remotely by attacking the connection between hospital laboratory devices and medical record systems.

29 Aug 2018

UCI research team uncovers new unexpected mode of neurotransmitter-based communication

Researchers at the University of California, Irvine School of Medicine have discovered the first example of a novel mode of neurotransmitter-based communication.

22 May 2018

Very low carbohydrate diet may improve blood sugar control in type 1 diabetes

A new study led by researchers at Boston Children’s Hospital has shown that a very-low-carbohydrate diet can improve blood sugar control among people with type 1 diabetes.

7 May 2018

Very-low-carb diets found to improve blood sugar control in type 1 diabetes

ery-low-carbohydrate diets can improve blood sugar control in type 1 diabetes, with low rates of hypoglycemia and other complications, according to an online patient survey.

7 May 2018

Advanced insulin pump system can also manage type 1 diabetes in children, study shows

The MiniMed 670G insulin pump system (Medtronic, Northridge, California) can improve glycemic outcomes in children with type 1 diabetes as young as 7 years of age, according to an industry-funded study.

19 Mar 2018

Adults as likely to develop type 1 diabetes as children, research finds

Type 1 diabetes is not predominantly a 'disease of childhood' as previously believed, but is similarly prevalent in adults, new research published in the Lancet Diabetes & Endocrinology shows.

30 Nov 2017

EKF Diagnostics and Ortho Clinical Diagnostics collaborate on a new diabetic ketoacidosis assay

Ortho Clinical Diagnostics and EKF announce an agreement that allows Ortho customers to access to Beta-Hydroxybutyrate assay.

From EKF Diagnostics 12 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes

A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.

13 Sep 2017

New research aims to generate in vitro vascularized pancreatic islets from hPSCs

Tiny packets of cells called islets throughout the pancreas allow the organ to produce insulin. Type 1 diabetes -- also known as juvenile diabetes - tricks the immune system into destroying these islets.

23 Aug 2017

3U researchers discover biological marker that could predict development of Type 1 diabetes

A significant finding has been made by the 3U Diabetes Consortium, of Dublin City University, Maynooth University and the Royal College of Surgeons in Ireland, which has the potential to contribute to the identification of biological markers that predict the development of Type 1 diabetes, a chronic autoimmune disease.

27 Mar 2017

Study finds reduction in HbA1c levels with in-home use of hybrid closed-loop insulin delivery system

A pivotal registration trial to evaluate in-home use of the Medtronic MiniMed(r) 670G hybrid closed-loop insulin delivery system over 3 months showed a significant reduction in HbA1c levels for both adolescents and adults with type 1 diabetes.

13 Feb 2017

New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease.

2 Dec 2016

FDA approves Medtronic's ‘artificial pancreas’ for type 1 diabetes patients

The U.S. Food and Drug Administration today approved Medtronic's MiniMed 670G hybrid closed looped system, the first FDA-approved device that is intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses in people 14 years of age and older with type 1 diabetes.

28 Sep 2016

Detecting diabetes’ deadly ketones

A simple, hand-held breath testing device that detects deadly ketones has been developed by University of Sydney researchers. The device could mean an end to finger-prick blood tests for diabetes patients.

26 Aug 2016

Triple therapy approach helps Type 1 diabetes patients improve blood sugar control, lose weight

A combination of three medications—dapagliflozin, liraglutide and insulin—helped people with Type 1 diabetes improve blood sugar control and lose weight, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Aug 2016

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

28 Jul 2016

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015